GSK5764227

DRUG3 trials

Sponsors

GlaxoSmithKline, University Health Network, Toronto

Conditions

NeoplasmsRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active, not recruitingNCT05277051

GlaxoSmithKlineNeoplasms

Start: 2022-03-22End: 2027-08-31Updated: 2026-06-25

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

RecruitingNCT07277270

GlaxoSmithKlineNeoplasms

Start: 2025-12-03End: 2028-09-29Target: 84Updated: 2026-01-07

Phase 2

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

RecruitingNCT07408063

University Health Network, TorontoRecurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2026-04-27End: 2031-03-01Target: 30Updated: 2026-04-29